hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06387472 id: 23-007636 briefTitle: DermAI to Evaluate Human Factor of Testing overallStatus: RECRUITING date: 2024-04-29 date: 2024-08-01 date: 2024-12-31 date: 2024-04-29 date: 2024-04-29 name: Mayo Clinic class: OTHER briefSummary: The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home. conditions: Contact Dermatitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 150 type: ESTIMATED name: AI algorithm to evaluate photographs of skin test patch regions name: Allergen Patch measure: Classification of test site region reaction measure: Classification of test site region using a 5-point scale measure: False Positive Rate measure: False Negative Rate measure: Early termination of testing measure: Participants that removed patches early measure: Adverse events related to allergen exposure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224 country: United States name: Laura Pacheco-Spann role: CONTACT phone: 904-953-0408 email: FLAQHSCS@mayo.edu name: Matthew Hall, MD role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 hasResults: False
nctId: NCT06387459 id: 2022M3C1A3090827 briefTitle: Feasibility of Fabric Orthosis for Knee Support in Elderly Gait Improvement overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-14 date: 2026-05-14 date: 2024-04-29 date: 2024-04-29 name: Seoul National University Hospital class: OTHER name: Ministry of Science and ICT briefSummary: This pilot clinical trial assesses the safety and feasibility of a novel fabric-type orthosis designed to mimic the knee extensor muscles and improve gait in elderly patients with mobility impairments due to conditions like sarcopenia, diabetes, or knee osteoarthritis. The study aims to test this orthosis in a real- world setting to see if it can enhance mobility and stability for elderly individuals, potentially reducing falls and improving quality of life. A total of 30 participants aged 65 and older will be recruited to use this orthosis across multiple sessions, where their gait will be analyzed under various conditions to measure the device's impact on walking speed, stability, and muscle activation. conditions: Gait conditions: Fall conditions: Orthotic Devices studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Fabric-Type Knee Extensor Muscle-Mimicking Orthosis measure: Completion Rate measure: Dropout Rate measure: User Feedback measure: 6-Minute Walk Test measure: 10-Meter Walk Test measure: Surface Electromyography measure: Gait Analysis sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387446 id: RB-P00044611 briefTitle: Allogeneic Valve Transplantation overallStatus: RECRUITING date: 2024-05-01 date: 2027-06-01 date: 2027-06-01 date: 2024-04-29 date: 2024-04-29 name: Boston Children's Hospital class: OTHER briefSummary: Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve. conditions: Valve Heart Disease conditions: Valve Disease, Heart conditions: Valve Disease, Aortic studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 4 type: ESTIMATED name: Valve transplant measure: Valve Regurgitation measure: Valve Annulus Growth measure: Leaflet Growth measure: Ventricular Function measure: Survival sex: ALL minimumAge: 30 Days maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Boston Children's Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Sitaram Emani, MD role: CONTACT lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06387433 id: mHealth id: SG-222/R3-05/RDC/DUHS/1478 type: OTHER_GRANT domain: National Institutes of Health Pakistan briefTitle: Effectiveness of an mHealth Mobile App acronym: mHealth overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-20 date: 2025-08 date: 2025-08 date: 2024-04-29 date: 2024-04-29 name: Dow University of Health Sciences class: OTHER name: National Institutes of Health (NIH) briefSummary: Type II diabetes is a serious challenge for Pakistan. Not using medications properly increases healthcare costs and diabetes-related deaths. A mobile app in local language can improve medication adherence and self-management among diabetics. Therefore, in this 18 months long study we will develop a diabetes-related mobile application in Urdu, and will conduct a trial to assess whether it improves medication compliance and self-management, and how much economical this app would be compared to the usual standard of care for type II diabetics in Pakistan. This trial will be conducted at the National Institute of Diabetes and Endocrinology Karachi. The study participants will be divided in two groups. Only one group will use this application. We will measure medication compliance and self-management through diabetes-specific blood test and self-reporting questionnaires between two groups. We will also determine how much economic costs would be saved by using this app to improve medication compliance conditions: Type II Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 160 type: ESTIMATED name: mobile app use measure: adherence to medication measure: self-management among diabetics measure: Intervention usability measure: economic effectiveness of the app sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of Diabetes and Endocrinology city: Karachi state: Sindh country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06387420 id: AK117-206 briefTitle: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2026-04 date: 2027-04 date: 2024-04-29 date: 2024-04-29 name: Akeso class: INDUSTRY briefSummary: This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML. conditions: ACUTE MYELOID LEUKEMIA; AML studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: AK117 name: Azacitidine name: Venetoclax name: Placebo measure: Phase 1b: Number of participants with dose limiting toxicity (DLT) measure: Phase 1b/2: Number of participants with adverse events (AEs) measure: Phase 1b/2: Composite complete remission rate (CCR) measure: Overall response rate (ORR) measure: Time to response (TTR) measure: Time to CCR (TTCCR) measure: Duration of response (DoR) measure: Duration of CCR (DoCCR) measure: Rate of CCR Without Minimal Residual Disease (CCR MRD-) measure: Event-free survival (EFS) measure: Overall survival (OS) measure: Peak of Serum Concentration (Cmax) measure: Anti-drug antibody (ADA) measure: Receptor occupancy (RO) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College city: Tianjin country: China name: Jianxiang Wang role: CONTACT lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06387407 id: 2024037K briefTitle: Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-10 date: 2025-11-25 date: 2024-04-29 date: 2024-04-29 name: The Affiliated Hospital Of Guizhou Medical University class: OTHER briefSummary: According to published studies, the effects of genetic polymorphisms in the ABCB1 and CES1 genes on the blood concentration of dabigatran are controversial, and it is not clear whether dabigatran dosage and dosing intervals need to be adjusted according to genotype or other covariates in Chinese subjects. For these purposes, we will include patient demographics, genetic polymorphisms, and PK data based on a population pharmacokinetic study of dabigatran ester in healthy Chinese subjects to analyze the effect on dabigatran pharmacokinetics.
The aim of this study was to develop a population pharmacokinetic model to understand the relationship between dabigatran-related genes and dabigatran plasma levels after a single oral dose in healthy Chinese subjects and patients, and to analyze the effects of genetic variation on the efficacy and safety of dabigatran etexilate. conditions: Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED name: Dabigatran Etexilate 150mg measure: Plasma drug concentration sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387394 id: M21-416 briefTitle: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence overallStatus: RECRUITING date: 2024-04-22 date: 2025-12-27 date: 2026-01-26 date: 2024-04-29 date: 2024-04-29 name: AbbVie class: INDUSTRY briefSummary: The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP).
BOTOX is being investigated for the treatment of Muscle Masseter Prominence. In Period 1, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment, placebo or BOTOX. There is a 1 in 4 chance that participants will be assigned to placebo. In Period 2, eligible participants can receive an optional open-label retreatment of BOTOX. Approximately 200 adult participants with MMP will be enrolled in the study at approximately 20 sites in the United States.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires. conditions: Masseter Muscle Prominence studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: BOTOX name: Placebo measure: Composite Achievement of MMP Severity Improvement and at Least a 2-Grade Improvement from Baseline by Both Investigator-Rated MMPS and Participant-Rated MMPS-P measure: Number of Participants with Adverse Events (AEs) measure: Percentage of Participants Achieving Investigator-Rated MMPS Improvement Over Time measure: Percentage of Participants Achieving Participant-Rated MMPS-P Improvement Over Time measure: Percentage of Participants who Responded as "Very satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT) measure: Percentage of Participants who Responded as "Much improved" or "Moderately improved" on the MMP Participant Self-Assessment of Change (MMP-PSAC) measure: Percentage of Participants who Responded as "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) measure: Change from Baseline in Lower Facial Shape Questionnaire-Impact Assessment (LFSQ-IA) Summary Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Delricht Research /ID# 249825 status: RECRUITING city: New Orleans state: Louisiana zip: 70115 country: United States lat: 29.95465 lon: -90.07507 facility: Clarkston Dermatology /ID# 248888 status: RECRUITING city: Clarkston state: Michigan zip: 48346 country: United States lat: 42.73586 lon: -83.41883 hasResults: False
nctId: NCT06387381 id: CYYY-KY-2024-048-01 briefTitle: 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease overallStatus: RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2026-12-31 date: 2024-04-29 date: 2024-04-29 name: First Affiliated Hospital of Chongqing Medical University class: OTHER briefSummary: As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases. conditions: PSMA conditions: FAP conditions: Positron-Emission Tomography studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: 68Ga-PSFA measure: Diagnostic efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Chongqing Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400016 country: China name: Xiaoyang Zhang, PhD role: CONTACT phone: 023-89011755 email: zhangxy@mail.bnu.edu.cn lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06387368 id: HE-202303 briefTitle: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-03 date: 2028-08 date: 2024-04-29 date: 2024-04-29 name: Health Science Center of Xi'an Jiaotong University class: OTHER name: LinkDoc Technology (Beijing) Co. Ltd. name: Huazhong University of Science and Technology briefSummary: This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer. conditions: Pancreatic Cancer Non-resectable studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 488 type: ESTIMATED name: Huaier Granule name: Capecitabine measure: Overall survival measure: Objective response rate measure: Progression free survival measure: Conversion surgery rate measure: The incidence and severity of adverse events (AE) and severe adverse events (SAE) measure: The incidence and severity of ADR, severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06387342 id: CF102-222PC briefTitle: Namodenoson Treatment of Advanced Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-07-15 date: 2026-07-15 date: 2026-12-15 date: 2024-04-29 date: 2024-04-29 name: Can-Fite BioPharma class: INDUSTRY briefSummary: This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients. conditions: Pancreatic Adenocarcinoma conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open-label study primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Namodenoson 25mg measure: Adverse Events measure: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline measure: Objective response rate measure: Progression free survival measure: Disease control rate measure: Duration of response measure: Overall survival measure: Quality of Life evaluation with EORTC QLQ-C30 measure: Quality of Life evaluation with EORTC QLQ-PAN26 measure: Pharmacokinetics of namodenoson: Cmax measure: Pharmacokinetics of namodenoson: Cmin measure: Pharmacokinetics of namodenoson: AUC(0-12) measure: Cancer antigen 19-9 (CA 19-9) measure: Carcinoembryonic Antigen (CEA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rabin Medical Center Institute of Oncology city: Petach Tikva zip: 49100 country: Israel name: Salomon M Stemmer, MD role: CONTACT lat: 32.08707 lon: 34.88747 hasResults: False
nctId: NCT06387329 id: WRNMMC-2023-0438 briefTitle: Bladder Botox UTI Antibiotic Prophylaxis overallStatus: RECRUITING date: 2024-04-04 date: 2025-06-30 date: 2025-06-30 date: 2024-04-29 date: 2024-04-29 name: Walter Reed National Military Medical Center class: FED briefSummary: Overactive bladder (OAB) is a common condition with a prevalence of 17% in the general population that significantly affects quality of life. Intradetrusor onabotulinumtoxinA injections are an advanced therapy for OAB as well as interstitial cystitis/bladder pain syndrome (IC/BPS). The most common adverse event following intradetrusor injection of onabotulinumtoxinA in urinary tract infection (UTI), which occurs in 8.6-48.1% of patients. To prevent UTIs, patients are given a course of antibiotics, however the ideal prophylactic regimen has not been determined for the timing, duration, and type of antibiotic. Four retrospective studies in the literature address this question with variable conclusions, and there are no prospective studies. Identifying the ideal regimen is important for preventing UTIs as well as minimizing antibiotic use to prevent adverse effects and development of antibiotic resistance.
The population to be studied will be female patients 18 years and older who are patients of the urogynecology and urology clinics at Walter Reed National Military Medical Center with a diagnosis of OAB or IC/BPS and have chosen to be treated with intradetrusor onabotulinumtoxinA injections. It will be a non-blinded randomized controlled noninferiority trial in which the patients are randomly placed into 2 groups. The first group will receive a 3 day course of twice daily oral nitrofurantoin 100mg starting at the time of the procedure, and the second group will receive a single dose of 100mg oral nitrofurantoin at the time of the procedure.
The patients will be screened at the clinic at the time that they schedule their intradetrusor onabotulinumtoxinA injection appointment or by phone 1-2 weeks prior to their procedure. If the patient agrees to participate in the study then they will be instructed to give a urine sample for urinalysis and culture 1 week prior to the procedure appointment to exclude existing UTI. If a UTI is diagnosed at this time they must complete treatment prior to the procedure or will need to reschedule their procedure. On the day of the procedure patients will receive the clinic standard 10ml of 2% viscous lidocaine through the urethra 10-20 minutes prior to the procedure, and may be offered 5-10mg oral diazepam at the discretion of the treating physician. All patients will be given 200mg of phenazopyridine and 100mg of nitrofurantoin prior to the initiation of the procedure. The procedure will take place as directed by the treating physician per standard operating procedure.
A urinalysis and urine culture will be placed for all study participants at time of their procedure appointment in case they have symptoms of UTI, and they will be instructed to follow up with the research team by phone if they have concerns for a UTI. Patients will be contacted 30-45 days after the procedure by phone, email, or message through genesis and asked about any UTI symptoms, UTI diagnoses and secondary outcomes during the 30 days following the procedure. Data will be analyzed for the primary outcome of UTI rates in the 30 days following intradetrusor onabotulinumtoxinA injection. conditions: Overactive Bladder conditions: Bladder Pain Syndrome studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Nonblinded, randomized, noninferiority trial of single dose nitrofurantoin vs 3 day twice daily course of nitrofurantoin for prevention of post-procedure urinary tract infections after intradetrusor onabotulinumtoxinA injections for OAB and IC/BPS. primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Nitrofurantoin 100 MG measure: Urinary tract infection measure: Urinary tract infection symptoms measure: Urinary retention measure: Adverse effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Walter Reed National Military Medical Center status: RECRUITING city: Bethesda state: Maryland zip: 20899 country: United States name: Jordan Gisseman, MD role: CONTACT phone: 301-400-2468 email: jordan.gisseman.mil@health.mil lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06387316 id: 2023-1526 briefTitle: Cephalic Phase Responses to Nutritive and Non-Nutritive Sweeteners overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-26 date: 2024-04-17 date: 2025-03-30 date: 2024-04-29 date: 2024-04-29 name: Purdue University class: OTHER briefSummary: This study will focus on changes in blood sugar in response to tasting different types of sweeteners using continuous glucose monitoring (CGM) technology. conditions: Pre Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: solutions are coded whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: No Oral Stimulation name: Oral water stimulation name: Oral Salt Stimulation name: Oral Sucralose Stimulation name: Oral Sucrose stimulation measure: Blood glucose concentration sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Purdue University city: West Lafayette state: Indiana zip: 47907 country: United States lat: 40.42587 lon: -86.90807 hasResults: False
nctId: NCT06387303 id: HSR230492 briefTitle: Pain Control and Quality of Recovery After Intravenous Methadone Versus Intrathecal Morphine in Major Abdominal Surgery overallStatus: NOT_YET_RECRUITING date: 2024-05-12 date: 2026-05-11 date: 2026-05-11 date: 2024-04-29 date: 2024-04-29 name: University of Virginia class: OTHER briefSummary: Moderate to severe postoperative pain is relatively common after major abdominal surgery and is associated with less than optimal surgical experience, poor quality of recovery, and development of persistent postsurgical pain. Opioids remain a major component of postoperative pain management. Side effects of opioids used for treatment of postoperative pain include constipation, pruritus, nausea, and vomiting.1,2 Enhanced recovery after surgery (ERAS) protocols involve utilization of multimodal analgesia. Analgesic techniques used include epidural analgesia, nerve blocks, and Intrathecal (IT) administration of morphine. IT morphine reduces postoperative opioid requirement for 18-24 hours after major abdominal surgery and reduces hospital length of stay (LOS) compared with epidural analgesia.3,4 Significant number of patients that receive IT morphine still experience moderate to severe postoperative pain.5 Additionally, many patients refuse the invasive procedure or cannot receive IT morphine due to procedure contraindications; thrombocytopenia and/or coagulopathy.6